As from September 1, 2024, Scandion Oncology A/S, will change Certified Adviser to Vator Securities AB. This information is distributed at the request of the Certified Adviser, Västra Hamnen Corporate Finance AB. For further information, please call Västra Hamnen Corporate Finance AB on +46 40 20 02 50.
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 27.03. | Scandion Oncology A/S: Scandion Oncology Announces Results of Annual General Meeting | The Annual General Meeting 2025 of Scandion Oncology A/S in liquidation (the "Company") was held on 27 March 2025 at 2:00 p.m.
All proposals were adopted in accordance with the notice.As such, the Company... ► Artikel lesen | |
| 13.03. | The observation status for Scandion Oncology A/S is updated | On February 27, 2025, the shares and equity rights in Scandion Oncology A/S (the "Company") were given observation status with reference to information that the Company's board of directors would... ► Artikel lesen | |
| 13.01. | Scandion Oncology A/S: Scandion Oncology announces final data from the CORIST trial and is ready to move into a randomized phase II Proof of Concept trial in Colorectal Cancer | Scandion Oncology, an innovative drug efflux pump inhibition company using biomodulation capability to revert drug resistance, announces final data from CORIST trial part 1, 2 and 3. In this phase I/II... ► Artikel lesen | |
| 30.08.24 | Nasdaq Stockholm AB: Change of Certified Adviser for Scandion Oncology A/S | As from September 1, 2024, Scandion Oncology A/S, will change Certified Adviser
to Vator Securities AB.
This information is distributed at the request of the Certified Adviser, Västra
Hamnen Corporate... ► Artikel lesen |
